Patents by Inventor Matthew David Disney

Matthew David Disney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR INHIBITION OF ALPHA-SYNUCLEIN mRNA USING SMALL MOLECULES
    Publication number: 20230054976
    Abstract: A sequence-based design has provided a group of small molecules that target the IRE structure and inhibit SNCA translation in cells, which are named synucleozid compounds. The synucleozid compounds have a diphenyloxo- or diphenylamino-benzimidazole or indole core with various terminal amino or heterocycle groups as substituents.
    Type: Application
    Filed: December 18, 2020
    Publication date: February 23, 2023
    Inventors: Matthew David DISNEY, M. Maral MOURADIAN
  • COMPOUNDS AND MODULES FOR INHIBITION OF PRE-miR-21 AND THEIR USE IN TREATMENT OF CERTAIN CANCERS
    Publication number: 20230002329
    Abstract: Small molecule compounds and corresponding dimers having inhibitory activity against pre-miR-21 RNA and related methods for treatment of neoplastic disease such as cancer and especially cancers expressing miR-21 are disclosed.
    Type: Application
    Filed: October 29, 2020
    Publication date: January 5, 2023
    Applicant: The University of Florida Research Foundation, Inc.
    Inventors: Matthew David DISNEY, Jessica L. CHILDS-DISNEY
  • RNA targeting compounds and methods for making and using same
    Patent number: 9260476
    Abstract: Disclosed are RNA targeting compounds, methods for using the subject RNA targeting compounds to treat myotonic dystrophy and other diseases are also disclosed.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: February 16, 2016
    Assignee: The Research Foundation for The State University of New York
    Inventor: Matthew David Disney
  • RNA TARGETING COMPOUNDS AND METHODS FOR MAKING AND USING SAME
    Publication number: 20140212945
    Abstract: Disclosed are RNA targeting compounds, methods for using the subject RNA targeting compounds to treat myotonic dystrophy and other diseases are also disclosed.
    Type: Application
    Filed: November 6, 2013
    Publication date: July 31, 2014
    Applicant: The Research Foundation for the State University of New York
    Inventor: Matthew David Disney